MilliporeSigma @ INTERPHEX 2018

Millipore Sigma Logo
Mobius® Power MIX Single-use Mixers- Increase Your Capacity, Not Your FootprintM3159_171201_829 copy

The Mobius® Power MIX family of single-use mixers combines high performance mixing technology with design features that make it easy to use. Extended sizes (2500 and 3000L) will be introduced at Interphex in April 2018. All  sizes (100L up to 3000L) include our proven impeller design and motor based on NovAseptic® magnetically coupled mixing technology. Every model efficiently mixes the most challenging buffers, media and biopharmaceutical ingredients. Our newly extended sizes can increase your capacity without increasing your footprint.

Visit MilliporeSigma at INTERPHEX in Booth #2841!
Learn more:

Posted in Uncategorized | Leave a comment

SP Scientific @ INTERPHEX 2018

SP Brands Logo_2016

SP Scientific Pilot to Production – Range of standard & custom freeze dryers, autoloading systems & process skids produces Freeze Dryer Innovation & Excellence. SP is one of the most technically innovative freeze drying manufacturers with a focus on understanding the needs of researchers and dedicated to providing quality equipment with superior application and technical support. Our brands provide complete project support from design specifications through engineering, fabrication, GAMP 5 documentation packages, installation, service and parts, as well as world-class vial handling solutions.

Visit SP Scientific in Booth #2523!

Learn more about SP Scientific:

Posted in Uncategorized | Leave a comment

Finding New Roads

Finding New Roads

Customer demands are shifting fast, and new designs are helping manufacturers navigate the market apex

By Karen Langhauser, Chief Content Director, Pharmaceutical Manufacturing

Just in time for its 115-year anniversary, Harley-Davidson unveiled what the iconic motorcycle manufacturer is touting as its largest ever product development project – eight redesigned cruisers and five new touring bikes for 2018.

But it’s not just about celebrating its 115th anniversary; Harley-Davidson is losing market share and watching its baby-boomer customer base age out of riding.

Intensive customer research has revealed that a large part of the problem has to do with design. Essentially, next-generation riders want bikes with more sophisticated packaging.

As you will read in Pharmaceutical Manufacturing’s packaging issue ( , the drug industry can identify with Harley-Davidson’s struggles. The rising popularity of new biological drug formulations is creating unique packaging challenges and equipment demands. Due to the complex nature of these next-generation (mostly liquid injectable) drugs, they are particularly sensitive to leachables. According to industry expert Jerry Martin (, each biosimilar will require different precautions and react with packaging differently.

Our recent product focus discussion ( found that packaging equipment suppliers are designing equipment to meet the specific needs prioritized by the modern-day pharmaceutical industry. Many new biologics are in the form of targeted therapies and personalized medicines, thus driving drug manufacturers to produce treatments more efficiently and in smaller quantities. These new roads demand a more flexible, scalable approach to meeting the industry’s packaging needs.

In the drug industry, this move toward smaller, more responsive production lines is causing an increased need for contract packaging organizations. These contract packagers are tasked with a challenge similar to the one Harley-Davidson is facing: drug manufacturers are looking for more design innovation in packaging – and they are relying on contract packagers to provide it. And as you can read in a recent Pharmaceutical Manufacturing cover story (, contract packagers are hammering down.

Harley-Davidson, too, appears to have delivered, by coming up with a new line of bikes that maintain the classic Harley feel but on a lighter, more powerful, more high-tech frame. Harley says all eight of the 2018 cruisers offer quicker acceleration, better braking and handling than previous models. The new cruisers are even sporting modern features like LED, USB ports, digital instrument screens and keyless ignition.

Not surprisingly, agility is key. Harley-Davidson’s new bikes will enable a next-generation of riders to steer and corner more easily, and new drug packaging will enable drug manufacturers to navigate the twists and turns of modern pharma market demands. New paths have been paved, and for both industries, the adventure continues.

Posted in Uncategorized | Leave a comment

That’s a Wrap

Penetrating the layers of 2017 regulatory actions helps pharma construct a productive narrative
Karen Langhauser, Chief Content Director, Pharmaceutical Manufacturing

Unfortunately for mummies, their cinematic fame somewhat fell by the wayside when zombies took over as pop culture’s new favorite not-quite-dead terror.

Researchers, however, have not yet lost interest in mummies (apparently due to a widespread shortage of zombies in the scientific research community) and have now enlisted the help of X-ray technology to further their work.

Just recently – and for the first time ever – scientists, researchers and art curators utilized Argonne National Laboratory’s Advanced Photon Source synchrotron technology to look inside the linen-wrapped remains of an 1,800-year-old Egyptian mummy. The technology – the brightest X-ray source in the Western Hemisphere – speeds up electrons along a 3,600-foot circular track to produce high energy X-rays. The APS technology is used for research across a multitude of scientific areas on a regular basis. In the pharma industry, the X-ray technology can offer researchers a picture of a protein’s structure, which has aided in the development of inhibitor drugs such as Abbott Labs’ HIV drug, Kaletra, and Roche’s melanoma drug, Zelboraf.

As I wrote the December cover story for Pharmaceutical Manufacturing, ( researchers in Illinois were using this advanced X-ray technology to non-invasively investigate the mummified remains of a five-year-old girl unearthed in Egypt in 1911 (I’ll let you decide whose job is more fun). While most would argue that pharma regulations come wrapped in red tape rather than resin-soaked linens, both tasks involve penetrating layers upon layers of details.

In the mummy’s case, using X-rays to study the wrappings, skeleton and internal matter enables researchers to gather clues that will shine light on the life, culture and trade networks of the Roman Empire. When speaking about pharma and regulatory intelligence, gathering and analyzing regulatory data against the backdrop of the industry enables manufacturers to derive meaningful outputs that can be used to guide regulatory strategy.

Essentially, it’s all about constructing a story, piece by piece. Personalized medicines, global harmonization and quality were the stars of 2017’s regulatory tale, while political change in the United States and Europe left mysteries that have yet to unfold.

X-ray technology is valuable to the study of these ancient artifacts because the mummies will be completely unharmed during the process. And it is our hope at Pharmaceutical Manufacturing that our yearly recap will provide our readers with a painless review of 2017 regulatory actions.

We can’t promise you immortality, but maybe we can settle on helping to preserve your regulatory sanity.

Posted in Uncategorized | Leave a comment

Changing Expectations in the Pharma Outsourcing Market

Nice Insight – Interphex 2017 March 23, 2017

While demand for outsourcing services remains strong in the pharmaceutical industry,spending is down and further decreases are expected. Service provides are faced with increasing competition and growing pressure to differentiate.

Pharmaceutical Market Remains Strong…

The global pharmaceutical market is currently expanding at a healthy compound annual growth rate (CAGR) of 6.3% according to EvaluatePharma. In addition, global pharma R&D spending is increasing at a CAGR of 2.8%. As a result, by 2022, the research firm expects 50% of added revenues to be derived from new products currently in the R&D pipeline.1 The market for active pharmaceutical ingredients (APIs) is growing at a similar CAGR (6.5%) and will reach $225 billion in 2021, according to Mordor Intelligence.2

Not surprisingly, healthy growth rates are also predicted for the global pharmaceutical contract manufacturing and research markets. Mordor Intelligence predicts the contract manufacturing sector will expand at a CAGR of 6.4% to reach $84 billion in 20213, while Grand View Research estimates the global healthcare contract research industry will grow at greater than 6.0% annual and be valued at $45.2 billion by 20224.

But Is Changing…

While growth remains strong, the pharmaceutical industry is faced with pricing pressure and expectations for new medicines that provide measureable added value. Drug manufacturers are challenged to be first to market with highly efficacious, cost-effective and demonstrably safe products and are consequently seeking efficiencies in all aspects of their operations. Reasons for outsourcing to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are thus changing.

While outsourcing activities were initially driven by the desire to reduce costs, for respondents to the 2016 Nice Insight CDMO Outsourcing survey, the top five drivers for outsourcing were improving quality and efficiency, gaining competitive advantage and operational / technical expertise and reducing the risk of supply shortages. 5 In 2017, the top reason for participants in 2017 Nice Insight Contract Development and Manufacturing Survey is access to specialized technologies.6 The other top four reasons are improving quality, gaining expertise, outsourcing is seen as a strategic activity and cost.

Similarly, for respondents to the 2017 Nice Insight Preclinical and Clinical Contract Research Survey, access to specialized technologies is the main driver for partnering with research firms.7 Other top reasons include improving quality, incorporating outsourcing in their strategic plans, and gaining access to operational, subject matter and regulatory expertise.

Contract service organizations that serve as long-term partners, act as extensions of their customers’ businesses and provide comprehensive, efficient, responsive and affordable support combined with access to novel and proprietary technologies will achieve the greatest success under these conditions.

With Continued M&A Activity …

Merger and acquisition (M&A) activity has occurred at a healthy pace in the pharmaceutical industry in recent years, including in the contract services sector. A total of 76 transactions involving service organizations were announced or completed in 2016, according to Capstone Partners, with sellers achieving high valuations with an average EBITDA multiple of 113.2x.8 Notably, nearly three quarters of the deals were made by strategic buyers. In the CDMO segment, Capstone reports that emerging and small pharma companies, which account for a growing percentage of pipeline candidates, require support across the full pharma development cycle from discovery through commercialization, which is driving M&A activity.8 The number of US CDMOs acquired in 2016 totaled 14.

The increasing complexity of clinical trials is driving demand for sophisticated CRO partners that have a broad range of advanced capabilities, according to Capstone.8 This need is a key driver of M&A activity in the CRO space.

CROs and CDMOs, as well as diversified testing, inspection and certification companies and private equity firms have also been busy acquiring analytical testing laboratories in order to meet the growing demand for cost-effective testing in the face of increasing regulatory requirements and the need to rapidly evaluate large numbers of pipeline candidates, according to Capstone.8

And Decreased Spending

Despite the healthy state of the market, the Nice Insight survey results for both the CDMO and CDMO sectors indicate a measurable decrease in spending by pharmaceutical companies on outsourcing activities.

Notably, the percentage of respondents to the 20165 and 20176 Nice Insight CDMO Outsourcing surveys with annual outsourcing expenditures of $50 million or more dropped from 71% to 56%, respectively. In addition, more respondents to the 2017 survey expect their companies to decrease (52%) rather than increase (39%) spending on contract development and manufacturing services over the next five years5 compared to 75% and 4%, respectively, in 20166.

A decrease in spending was also noted in the CRO sector; the number of drug manufacturers spending more than $50 million/year on contract research services dropped noticeably from 56% in 20169 to 47% in 20177, according to the Nice Insight CRO surveys. Also similarly, in 2016 nearly 75% of respondents expected spending on contract research services to increase9, while in 2017 that number was just 40%, with 50% predicting a decline in spending over the next five years7.

The reduced spending matches well the significant drop in the number of new drugs approved by FDA in 2016 – down from 41 in 201410 and 45 in 201511 to just 19 in 201612 as of November 29, 2016. On a positive note, around half of the respondents to the 2017 Nice Insight CDMO (55%)6 and CRO (48%)5 Outsourcing surveys expect their companies the number of CDMOs they partner with to increase.

Overall, however, the high level of M&A activity and the results obtained for the Nice Insight surveys suggest that competition in the CDMO and CRO marketplaces appears to be tightening, making it increasingly important for outsourcing partners to meet the quality, reliability, timeliness and other expectations of sponsor firms looking to outsource research, development and manufacturing activities.

BUT… Equipment spending Is Up!

Although they are decreasing spending on outsourcing, pharmaceutical companies appear to continue spending on equipment. Over one-third of respondents (38%) to the 2017 Nice Insight Pharmaceutical Equipment Survey have equipment budgets that exceed $100 million, a remarkable increase from 2016.13 In addition, 73% of respondents project budget increases in the coming years. A desire to increase productivity, lower costs, shorten the development timeline and access specialized technologies is driving the increased investment in equipment. The budget increases in 2017 may also indicate growing investments by small and emerging pharma companies to expand their in-house manufacturing capabilities.


  1. EvaluatePharma, “World Preview 2016, Outlook to 2022,” September 2016.
  2. Mordor Intelligence, “Global Active Pharmaceutical Ingredients Market – Growth, Trends & Forecasts (2016 – 2021),” September 2016. global-active-pharmaceutical-ingredients-api-market-industry.
  3. Mordor Intelligence, Global Pharmaceutical Contract Manufacturing Market – Trends and Forecasts (2016 – 2021) August 2016.
  4. Grandview Research Inc., “Healthcare CRO Market to Reach $45.2 Billion by 2022,” January2016,
  5. The 2016 Nice Insight Contract Development & Manufacturing Survey.
  6. The 2017 Nice Insight Contract Development and Manufacturing Survey.
  7. 2017 Nice Insight CRO survey,
  8. Capstone Partners, “Pharmaceutical Outsourcing: Q1 2017.” March 2, 2017.
  9. 2016 Nice Insight CRO survey,
  10. FDA, “New Molecular Entity and New Therapeutic Biological Product Approvals for 2014”
  11. FDA, “New Molecular Entity and New Therapeutic Biological Product Approvals for 2015”,
  12. FDA, “New Molecular Entity and New Therapeutic Biological Product Approvals for 2016”
  13. The 2017 Nice Insight Pharmaceutical Equipment Survey


Posted in Uncategorized | 1 Comment

Getting the Most out of your Single-use

By: GE Healthcare

Single-use equipment may be strategically adopted by biopharmaceutical manufacturers as a means by which to accelerate time to market, thereby serving patients more effectively and gaining a greater return on investment. Adoption of single-use equipment represents a shift in the responsibilities between supplier and end-user with respect to managing critical quality attributes.

Among these quality attributes are extractables/leachables, sterility assurance, integrity/leak assurance, and particulate load. Regulators across the globe have taken various approaches to lending guidance, either maintaining that today’s regulations and guidance are fully applicable to any modality of manufacturing (multi- or single-use), or deciding to embark on guidance intended to coalesce todays best practices.

Relative to multi-use equipment, a large fraction of this responsibility shifts to the suppliers. On the other hand, the end-user still retains full accountability for assuring that the single-use equipment is suitable for use and is being appropriately managed from a quality perspective. This shift in responsibility and the attendant regulatory challenges may cause hesitation on the part of the end-user as one works through development of control strategies that, by their nature, include an important element of reliance on the supplier’s quality management. 

GE Healthcare views the current state of the biopharmaceutical manufacturing industry as an opportunity to provide insights that delineate the differences between multi- and single-use equipment. In addition, sharing best practices of how supplier and end-user responsibilities must evolve are critical to ensure effective quality management of single-use equipment for biopharmaceutical manufacturing.


Posted in Uncategorized | Leave a comment

How to Build a Bio-manufacturing Facility for the Future: IT Infrastructure Integration

Bioprocess data is gathered in multiple instances throughout process development and manufacturing stages. An integrated facility strategy for data collection and storage can provide multiple benefits, including an enhanced security, facilitated data reporting, increased reliability, increased up-time, and overall quality improvements.

Specific examples include the following:

  • A centralized integrated IT infrastructure streamlines user account maintenance and simplifies user access. Computer policy settings are easily administered to the technical staff and the same account credentials are used on all equipment.
  • When cGMP data is stored and accessible from a central location, report creation, data trending and evaluation of batch run data is easier compared with if data is stored in multiple locations. An integrated automation solution will also improve process alarm management through remote monitoring, SMS text message notifications and a single workstation view of the entire factory.
  • Redundancy can be applied to critical components to ensure uninterrupted operation in the event of a hardware failure, for example, a failure in an interface terminal. Workstations are interchangeable for additional flexibility.

It is critical to design and plan for automation integration early in the facility design phase. The integration details for all equipment should be thoroughly specified to avoid redesign later, sufficient time should be allocated for equipment installation and wiring between buildings and rooms, and extra time should be planned for change control. It is also helpful to carefully plan integration activities in discrete elements that can be achieved during limited facility downtime.

In a globally competitive marketplace, tangible benefits of a fully integrated automation solution are no longer a nice to have – but a business requirement.

Posted in Uncategorized | Leave a comment